Navigation Links
DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
Date:2/10/2009

Crucell

Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6(R) production technology. The Company licenses its PER.C6(R) technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, Sanofi-Aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over 1000 people. For more information, please visit www.crucell.com

DSM Biologics

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6(R) human cell line as a production platform for recombinant proteins and monoclonal antibodies. The combination of the PER.C6(R) human cell line and DSM's manufacturing services provi
'/>"/>

SOURCE DSM Biologics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
2. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
5. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
6. Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc.
7. ProCure Signs Agreement with .decimal, Inc. to Purchase Patient-Specific Devices for Its Proton Therapy Center in Oklahoma City
8. Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries
9. Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers
10. University of Helsinki and ASM International renew research agreement on atomic layer deposition
11. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
(Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks ... Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original ... will increase healthcare worker safety and reduce financial costs. , CTI Electronics announces ...
(Date:6/30/2015)... ... 30, 2015 , ... Park Systems , world-leader in ... into new classes of Nanoscale Graphene-based materials poised to revolutionize industries such as ... of the 21st Century' by the researchers who were awarded the 2010 Nobel ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... SAN DIEGO, Jan. 6, 2011 Ardea Biosciences, Inc. ... top-line results from its Phase 2b study of RDEA594 ... the treatment of gout, allopurinol.  Allopurinol currently accounts for ... gout prescription medications; however, in controlled trials, only 30-40% ...
... Jan. 6, 2011 Vista Partners announced today ... (Nasdaq: OPXA ) and raised its twelve ... Analyst at Vista Partners stated, "Opexa announced yesterday that their ... treatment of Multiple sclerosis , is now positioned from ...
... 2011 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical ... focusing on the early diagnosis and preventive treatment of ... two U.S. events: the 28th J.P. Morgan Healthcare Conference ... Showcase (from January 10th to 12th, 2011). ...
Cached Biology Technology:Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 3
(Date:7/2/2015)... Fingerprint Cards has received an order ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... by smartphone manufacturers in Asia . The ... revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/24/2015)... 24, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Sharp has selected its industry-leading ... for its latest flagship smartphone device, the AQUOS ... million shipments of its fingerprint ID sensor technology, ... scalability and leadership in the biometrics market through ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... British Columbia researchers have identified a small virus that ... size, rescuing the infected zooplankton from certain death. The ... jumping genes found in other organisms. The study, ... Matthias Fischer, is published online today in Science Express. ...
... at managing environmental impacts of agriculture have spurred ... and natural fertilizers for commercial applications. Many organic ... other processing industries. In Mississippi, where the poultry ... each year, and annual chicken litter production is ...
... New University of Georgia research has identified a protein ... of the most common drugs used to treat pancreatic cancer. ... journal Cancer Research, found that a cell-surface protein ... reduced in function in two thirds of pancreatic tumors. By ...
Cached Biology News:'David and Goliath' viruses shed light on the origin of jumping genes: UBC study 2Chicken litter provides organic alternative to synthetic fertilizers 2Researchers find possible new treatment strategies for pancreatic cancer 2
4-Hydroxy-3-iodo-5-nitrophenylacetyl hapten is conjugated to BSA protein through lysine by amide bonds....
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
... Edwards (1996) • Provides key ... immunoassays, including RIA, ELISA and ... the photoluminescent and chemiluminescent labels ... also given on assay design ...
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
Biology Products: